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Neuroinflammation has a key role in the pathogenesis of perinatal brain injury. Caffeine,
a nonspecific antagonist of adenosine receptors (ARs), is widely used to treat apnea
of prematurity and has been linked to a decrease in the incidence of cerebral palsy
in premature infants. The mechanisms explaining its neuroprotective effect have not
yet been elucidated. The objective of this study was to characterize the expression of
adenosine and ARs in two neonatal rat models of neuroinflammation and to determine the
effect of A2aR blockade on microglial activation assessed through inflammatory cytokine
gene expression. We have used two rat models of microglial activation: the gestational
low protein diet (LPD) model, associated with chronic brain injury, and postnatal ibotenate
intracerebral injections, responsible for acute excitotoxicity injury. Adenosine blood levels
have been measured by Tandem Mass Spectrometry. The expression of ARs in vivo
was assessed using qPCR and immunohistochemistry. In vivo models have been
replicated in vitro on primarymicroglial cell cultures exposed to A2aR agonist CGS-21680
or antagonist SCH-58261. The effects of these treatments have been assessed on
the M1/M2 cytokine expressions measured by RT-qPCR. LPD during pregnancy was
associated with higher adenosine levels in pups at postnatal day 1 and 4. A2aR
mRNA expression was significantly increased in both cortex and magnetically sorted
microglial cells from LPD animals compared to controls. CD73 expression, responsible for
extracellular production of brain adenosine, was significantly increased in LPD cortex and
sorted microglia cells. Moreover, CD73 protein level was increased in ibotenate treated
animals. In vitro experiments confirmed that LPD or control microglial cells exposed to
ibotenate display an increased expression, at both protein and molecular levels, of A2aR
and M1 markers (IL-1β, IL-6, iNOS, TNFα). This pro-inflammatory profile was significantly
reduced by SCH-58261, which reduces M1markers in both LPD and ibotenate-exposed
cells, with no effect on control cells. In the same experimental conditions, a partial
increased of M1 cytokines was observed in response to A2aR agonist CGS-21680.
These results support the involvement of adenosine and particularly of its receptor A2aR
in the regulation of microglia in two different animal models of neuroinflammation.
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INTRODUCTION
Brain injury is one of the most important complication
related to preterm birth (1). From 25 to 50% preterm
infants display neurodevelopmental disabilities (2), with
dramatic consequences in terms of cost and impact on quality
of life.
Preclinical and clinical studies show that neuroinflammation
plays a central role in the pathogenesis of perinatal brain damage
(3–8). One of the first events following neuroinflammation is
activation ofmicroglia cells (9), that assume different phenotypes,
conventionally classified as M1 (pro-inflammatory) and M2
(anti-inflammatory, reparative) (10, 11).
During the inflammatory process, extracellular adenosine,
an ubiquitous molecule implicated in neuromodulation, reaches
high concentrations capable of activating the adenosine receptors
(ARs), denoted A1, A2a, A2b, and A3 (12, 13).
The most implicated adenosine receptor in
neuroinflammation is A2aR (14). Its expression in microglia is
usually low but increases following brain insults. In microglial
cells, activation of A2aRs has facilitating effects on the release of
cytokines (15) and on the change into amoeboid morphology
(16). Conversely, A2aR antagonists suppressmicroglia activation,
as described using in vitro (17, 18) and in vivo (18) studies.
To our knowledge, there are no data regarding the
adenosine pathway and neuroinflammation in preterm infants,
but nevertheless, the involvement of adenosine signaling in
prematurity is suggested by the clinical use of caffeine. Indeed,
caffeine, a non-specific antagonist of ARs widely used to
treat apnea of prematurity, not only improves survival and
reduces the duration of respiratory support, but also reduces
the incidence of cerebral palsy and cognitive delay (19).
Recently, a retrospective study demonstrated the existence of
high blood levels of adenosine in premature infants (20), with
the highest adenosine concentrations associated with the lowest
birthweight.
These data suggest a possible link between caffeine action,
adenosine plasma levels and an imbalance between the pro-
and anti-inflammatory profiles in very preterm infants usually
delivered following a perinatal inflammatory event. Whether a
similar link exists for adverse neurological outcomes in preterm
infants is not known and there is still little evidence relating to
effects of caffeine on brain development, especially at the cellular
and molecular levels (21).
Therefore, this study was aimed to characterize the
synthesis and expression of adenosine and its receptors in two
experimental animal models of neonatal neuroinflammation.
The effect of A2aR blockade was also studied in vitro using a
specific antagonist on microglial activation assessed through
pro- and anti-inflammatory cytokine gene expressions.
MATERIALS AND METHODS
Animals and Models
All experiments were carried out according to INSERM ethical
rules and approved by the institutional review board (Robert
Debré ethics committee, Paris, France, approval number Big
Project 01542.01). Sprague-Dawley rats (Janvier SAS, Le Genest-
St-Isle, France) were housed in temperature-controlled rooms
(24◦C), with 12 h light cycling and free access to chow and water
ad libitum.
Low Protein Diet (LPD) Model
After mating, dams were randomly allocated to either isocaloric
low-protein diet (LPD) (9% casein; as previously described
(22, 23), SAFE-diets Augy, France) or control diet (CTL)
(23% casein) during the gestational period. The control and
LP diets are balanced for energy intake assuming equivalent
consumption rates. At birth, damswere returned to standard diet.
Sex, birthweight and postnatal growth rates were determined.
Experiments research plan using this model is summarized in
Supplemental Figure 1.
Ibotenate (IBO) Model
Ten µg IBO diluted in Phosphate Buffered Saline (PBS) was
injected intracerebrally (i.c.) at postnatal day 5 (P5) to rat pups
of both sexes as previously described (24). Experiments research
plan using this model is summarized in Supplemental Figure 2.
The rat pups were killed and dissected at different postnatal
days (P1, P4, and P5). Blood was collected by exsanguination on
filter paper. Brains were collected, immediately snap frozen and
stored at −80◦C or immediately dissociated for microglia cells
isolation.
Antibodies and Reagents
Ibotenate (IBO, Tocris, Bristol, UK) was diluted in PBS
to prepare a stock solution of 20 mg/ml. SCH-58261
(SCH; Sigma Aldrich, Lyon, France S4568) and CGS-21680
hydrochloride hydrate (CGS; Sigma Aldrich, Lyon, France,
C141) were diluted in DMSO to a stock concentration of
10mM. Primary antibodies: anti-A2aR antibody (rabbit
polyclonal, ab3461); anti-CD73 antibody (rabbit polyclonal,
ab175396); anti-ionized calcium-binding adaptor protein-1
antibody (anti-Iba1, goat polyclonal, ab5076) were all purchased
from Abcam (France). Goat anti-rabbit and anti-mouse IgG
conjugated to horseradish peroxidase were purchased from
Sigma (Lyon, France). AlexaFluor R© 488-conjugated anti-goat
IgG and DAPI were from Life Technologies, while Cy3-
conjugated anti-rabbit IgG was from Jackson Immuno Research
Laboratories.
Microglia Cell Isolation and Primary
Culture
Brains were collected from control and LPD animals at P1
and P4 removing the cerebellum and the olfactory bulbs. The
tissues dissociation was performed using the Neural Tissue
Dissociation Kit and the gentleMACS Octo-Dissociator with
Heaters accordingly to the manufacturer’s instruction (Miltenyi
Biotec, Germany). CD11b positive cells were isolated from the
resulting homogenates using an anti-CD11b (microglia marker)
MicroBeads (Miltenyi Biotec, Germany) and multiMACSCell-24
separator (Miltenyi Biotec, Germany). After elution the sorted
microglia cells were stored at −80 for RNA extraction. In a
second set of experiments, microglia cells were magnetically
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sorted from control and LPD animals at P4 and after elution
pellet was isolated by centrifugation (300 g - 10min). Following
re-suspension in Dulbecco’s modified Eagle’s minimum
essential medium/Nutrient mixture F-12 (DMEM/F-12, Gibco)
supplemented with 10% fetal bovine serum (FBS, Gibco) and
1% penicillin/streptomycin (P/S), cells were maintained in
DMEM/F-12 supplemented with 10% FBS and 1% P/S at a
concentration of 5 × 105 cells/ml in 12-well culture plates.
The purity of isolated microglia cells was verified by Iba1
immunostaining (dilution 1/1,000). A medium change was
performed after 24 h and cells were treated as follows after
48 h. Microglial cells were treated with SCH-58261 (A2aR
antagonist) at 50 nM (17, 25) or CGS-21680 (A2aR agonist)
at 10µM (26, 27) or DMSO. For the IBO model, cells sorted
at P4 were treated with SCH, CGS or DMSO 20min before
adding ibotenate 300µM (28). After 6 h, cells were harvested
and RNA extracted for gene expression analysis. For cytokine
levels, supernatant (conditioned media) was collected after
a longer exposure time (12 h) and stored at −80◦C until
analysis.
RNA Extraction, Retro-Transcription and
Real-Time PCR
Total RNA was extracted from cortex using Qiazol reagent
and RNeasy mini kit (Qiagen, France) and from microglia
cells using the NucleoSpin RNA Plus extraction kit (Macherey-
Nagel, France) according to the manufacturer’s instructions.
RNA yield and purity were determined by spectrophotometry
absorption at 260 and 280 nm by means of a NanodropTM
apparatus (Thermofisher Scientific, MA, USA). Five hundred
ng of mRNA from cortex and 150 ng from microglia were
used to perform reverse transcription (iScript TM cDNA
synthesis kit, Biorad, France), respectively. qPCR measurements
were performed in duplicate using SYBR Green Super-mix
(Bio-Rad). The reaction conditions were as follows: 98◦C
for 10min (Polymerase activation), followed by 45 cycles at
95◦C for 5min, 60◦C for 10min and 72◦C for 10min. The
specificity of used primers was assessed with a melting curve
analysis and the results were quantified using the relative
standard curve methods. The relative mRNA expression for each
target gene was calculated after normalization respect to the
Rpl13 references gene. The primers sequences are available in
Supplemental Table 1.
Multiplex Cytokine Assay
Cytokines were measured using the Bio-Plex rat cytokine
multiplex kit (Bio-Rad). Calibration curves from recombinant
cytokine standards were prepared with serial dilutions in
the same media as the culture supernatant (DMEM/F-12
supplemented with 10% FBS and 1% P/S). Standards and
samples were analyzed in duplicate and blank values were
subtracted from all readings. All assays were carried out directly
in a 96-well filtration plate (Bio-Rad) at room temperature
and protected from light. Briefly, wells were pre-wetted with
culture supernatant, then beads together with either standard,
sample, or blank were added in a final volume of 50 µl,
and incubated together at room temperature for 30min with
continuous shaking. Beads were washed three times with 100
µl Bio-Plex wash buffer. A cocktail of biotinylated antibodies
(25 µl/well) was added to the beads for a further 30-min
incubation with continuous shaking. Beads were washed three
times, then streptavidin-phycoerythrin was added for 10min.
Beads were again washed three times and resuspended in 125
µl assay buffer. The fluorescence intensity of the beads was
measured using the Bio-Plex array reader. Bio-plex manager




For histological analysis after ibotenate i.c., injections, animals
were anesthetized with pentobarbital and transcardially perfused
with 4% paraformaldehyde in PBS. Brains were collected,
postfixed in 4% paraformaldehyde overnight, cryoprotected,
cut coronally in 10 µm-thick slices, and stained according to
standard protocols. After three washings of the slices with PBS,
the non-specific binding was blocked by incubating the tissue
sections with PBS-Triton 0.5%-gelatin 0.2% for 45min at room
temperature. Incubation with primary antibodies (rabbit anti-
CD73 1/1,000; goat anti-Iba1 1/1,000) was performed overnight
at 4◦C in PBS-Triton 0.5%-gelatin 0.2%. After rinsing three
times in PBS for 5min each, sections were exposed (1 h, room
temperature) to secondary species-specific antibodies (all at
1/1,000 dilution in PBS-Triton 0.5%-gelatin 0.2%) conjugated
to Alexa Fluor R© 488 or to Cy3. Nuclei were then labeled
with the fluorescent DAPI dye (1/10,000 in PBS). Stained
sections were mounted on microscope slides with Fluoromount-
G (SouthernBiotech).
Primary microglia cells cultured in micro-slide 8-well
chamber (Ibidi, Germany) and treated as reported above were
fixed in 4% paraformaldehyde for 30min at room temperature.
Each well was incubated with a blocking solution (PBS with 1%
BSA) for 1 h at room temperature and incubated overnight at
4◦C with goat anti-Iba1 (1/500) and anti-A2aAR (1/250). The
following day, after rinsing three times in PBS for 5min, cells
were incubated with secondary antibodies coupled to the green
and red fluorescence markers (1/500 dilution) for 1 h at room
temperature. Nuclei were visualized by staining the cells with
DAPI dye (1/10,000).
Cells were analyzed using a fluorescent microscope (Nikon
Eclipse Ti-E) and images captured with a 20X objective
(4 wells/group and 5 images/well). Fields used for quantitation
were randomly selected throughout the dish and focused
using phase contrast optics. Images from different emission
specters were acquired separately using the same parameters
and superimposed in the aftermath. For the analysis Image
J software (Research Service Branch, National Institutes of
Health, Bethesda, MD; http://rsb.info.nih.gov/ij/) was used.
Images were converted to binary images using an automatic
threshold function. The cells in each image were then defined
by outlining a mask image (ROI). For LPD experiments, as
the cells showed a significant difference in cell size due to
microglial activation, the fluorescence power was calculated
as the mean of all the pixel intensities of each individual
cell. For the ibotenate experiment, the fluorescence power was
calculated as an integrated density (i.e., the product of the
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FIGURE 1 | Adenosine blood levels in animals exposed to antenatal low
protein diet (LPD) and in control (Ctl) animals at postnatal day P1 and P4. Data
are shown as the mean value ± S.E.M. (*p < 0.05, ***p < 0.001, using
unpaired Student’s t-test).
mean of all the pixel intensities of each individual cell and
the ROI area). Cell size was calculated using Iba1-positive
cells as the product of number of pixels in ROI and the
conversion factor 0,103. Finally, the sums of the values for each
condition were normalized to control values for the statistical
analysis.
Statistical Analysis
The graphs and the statistical analysis were performed with
GraphPad Prism 5.0 (GraphPad Software, San Diego, CA).
Appropriate statistical analyses were carried out with a two-sided
alpha level of 0.05 or 95% confidence interval. For continuous
data, descriptive analyses were carried out employing means
and ± SEM, Parametric or non-parametric tests were used to
compare quantitative variables (Student’s t-test for independent
samples for comparisons between two groups and one-way
ANOVA with Newman Keuls post-test for comparisons of more
than two groups). A p-value < 0.05 was considered statistically
significant.
RESULTS
The LPD Model Influences Adenosine
Blood Levels and the Cerebral Expression
of Enzymes and Receptors Implicated in
Adenosine Metabolism
Prenatal LPD-induced malnutrition resulted in the absence of
postnatal mortality but fetal growth restriction with body weight
of the pups significantly lower from P0 to at least P4 compared
to the controls (Supplemental Figure 4). LPD pups at P1 and
P4 showed significantly higher adenosine blood levels compared
to the control pups (0.822 ± 0.088µM in Controls vs. 1.850 ±
0.355µM in LPD at P1, 0.598 ± 0.051µM in Controls vs. 1.464
± 0.215µM LPD at P4, see Figure 1).
In the pre-frontal cortex of LPD animals, the expression
of adenosine deaminase (ADA), adenosine kinase (ADK),
ectonucleoside triphosphate diphosphohydrolade-1 (Entpd1)
and cluster of differentiation 73 (CD73), enzymes involved in the
regulation of extracellular and intracellular adenosine levels, were
significantly increased at P1, compared to controls (Figure 2A).
The relative gene expression of intracellular enzymes ADA
and ADK were comparable between LPD and controls at
P4, whereas the two ectonucleotidases Entpd1 and CD73 are
persistently increased at this age in the LPD group, indicating
an increased extracellular production of adenosine. A2aR and
A2bR, the two main ARs with pro-inflammatory functions,
were significantly up-regulated at P1 and P4 in the cortex of
LPD pups (Figure 2B), suggesting a pro-inflammatory status
of the LPD brains. In contrast, no significant differences were
observed at a transcriptional level for A1 andA3 receptors, except
for an increased expression of A3R at P4 in the LPD group
(Figure 2B).
A2aR Expression Is Increased in Microglial
Cells Sorted From the Rat Pups Subjected
to Antenatal LPD
While most of the receptors display a similar pattern of
expression, A2aR expression was found significantly increased
in microglia cells sorted from LPD brains compared to controls,
both at P1 and P4 (Figure 3). Finally, no statistically significant
difference was observed in the expression of genes encoding for
the enzymes involved in the adenosine extracellular metabolism,
except for a transient andmild increase in the expression of CD73
at P1 in LPD animals.
The mean density of A2aR immunoreactivity in microglial
cells after 48 h in culture was significantly higher in LPD
compared to control group (Figures 4A,B). Moreover,
Iba1 immunoreactivity was found increased and cell size
reduced in LPD microglial cells, compared to control cells
(Figures 4C,D).
A2aR Antagonist Exposure Changes
Microglial Reactivity in vitro
After 2 day, significant increases in gene expression of both
M1 (IL-1β, IL-6, iNOS, TNFα) and M2 markers (IL-10, IL-
4ra) were detected in microglial cells sorted from LPD rat
pups, compared to control cells (Figure 5). SCH-58261, an A2aR
antagonist, induced a significant reduction in the expression
of M1 markers while no effect on M2 markers was detected
in LPD microglial cells. Conversely, the A2aR agonist CGS-
21680 was able to increase the mRNA levels of iNOS, TNFα
and IL-4ra in LPD microglial cells. No substantial effect of
either SCH-58261 or CGS-21680 was observed in control
cells.
A2aR Plays a Role in Excitotoxic-Induced
Microglial Activation
In the IBO model assessed 24 h after ibotenate injection, 1/3 of
Iba-positive cells surrounded the white matter lesion expressed
CD73, an enzyme responsible for the extracellular production of
adenosine in the brain (Supplemental Figure 5).
To assess the putative involvement of the adenosine
pathway in neuro-inflammation induced by excitotoxicity,
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FIGURE 2 | Comparisons of gene expression of enzymes involved in the production of adenosine (A) and its receptors (B) in animals exposed to LPD (black bars)
and in control animals (white bars) in prefrontal cortex. Data are shown as relative expression of control values normalized to 1 (*p < 0.05, **p < 0.01, ***p < 0.001,
using unpaired Student’s t-test). ADA, adenosine deaminase; ADK, adenosine kinase; Entpd1, ectonucleoside triphosphate diphosphohydrolade-1; CD73, cluster of
differentiation 73; A1R, adenosine A1 receptor; A2aR, adenosine A2a receptor; A2bR, adenosine A2b receptor; A3R, adenosine A3 receptor.
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FIGURE 3 | Comparisons of gene expression of enzymes involved in the production of adenosine and its receptors in microglial cells sorted from animals exposed to
LPD (black bars) and from control animals (white bars). Data are shown as relative expression of control values normalized to 1 (*p < 0.05, using unpaired Student’s
t-test).
magnetically sorted microglial cells from P4 control pups
were exposed to 300µM IBO for different lengths of time
from 2 to 12 h. The exposure to IBO was unable to
induce an increase in A1 and A2a receptor expression levels
after 2-h exposure (Figure 6). In contrast, a significant and
progressive increase in the gene expression of both receptors
was observed after 6- and 12-h IBO exposure. CD73 was
also found to be slightly but significantly increased, while no
difference was observed regarding A2b and A3 receptors gene
expression.
Frontiers in Neurology | www.frontiersin.org 6 September 2018 | Volume 9 | Article 605
Colella et al. Microglial Activation and Adenosine A2aR
FIGURE 4 | A2aR expression in microglial cells sorted from animals exposed to LPD. (A) A2aR (red) and Iba-1 (green) immunoreactivity microglial cells sorted from
LPD-exposed rat pups and control animals (scale bar: 50µm). (B,C) Quantification of mean fluorescence for A2aR and Iba-1 immunoreactivity in control and LPD
microglial sorted cells. (D) Quantification of cell size on Iba-1 positive cells. Data are shown as relative expression of control values normalized to 1 (**p < 0.01,
***p < 0.001, using unpaired Student’s t-test).
These results were confirmed at protein level using
immunocytochemistry (Figure 7). IBO exposure for 6 h was
associated with a significant increase in A2aR immunoreactivity
in microglial cells, while cell size and the Iba1 immunoreactivity
were found similar with and without IBO.
A2aR Modulation Is Involved in the
Regulation of M1-M2 Microglia Phenotype
in Excitotoxic-Induced Inflammation
In our in vitro model of excitotoxic activation of primary
microglial cells, highly significant increase in gene expressions
of IL1β, IL6, iNOS, TNFα, and IL10 were was observed in
response to 300µM IBO exposure for 6 h (Figure 8). This effect
was significantly reduced by SCH-58261 pre-treatment, 20min
before IBO challenge. Interestingly, SCH-IBO treated microglia
display a higher expression level of the M2 cytokine IL-4ra.
Pre-treatment with CGS-21680 induced down-regulation of
TNFα and IL4ra and up-regulation of IL6 gene expression in
IBO-treated cells, but had no effect on gene expressions of IL1β,
iNOS and IL10.
In another set of experiments, conditioned culture media
were collected after 12-h IBO exposure with or without
SCH-58261 pre-treatment, and cytokine concentrations were
assessed (Figure 9). While IBO induced higher IL1β and TNFα
concentrations in the culture media, the A2aR antagonist
SCH-58261 exposure was associated with a reduced cytokine
production in response to excitotoxic challenge.
DISCUSSION
This study strongly suggests that adenosine and the regulation of
its receptor A2aR play a role in neonatal brain inflammation and
microglial activation in rat.
Abundance of literature has demonstrated both in clinical
and preclinical studies that neuroinflammation is a relevant
component in the pathogenesis of prematurity-related brain
injury (3, 4, 9, 29–32). Interestingly, adenosine exerts a role in
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FIGURE 5 | A2aR modulation regulates the phenotype of microglial cells sorted from LPD animals. Quantification of gene relative expressions of M1 (A) and M2 (B)
proteins in microglial cells treated with or without SCH-58261 (A2aR antagonist) and CGS-21680 (A2aR agonist) sorted from control or LPD animals (*p < 0.05,
**p < 0.01, ***p < 0.001, using one-way ANOVA followed by Newman-Keuls post-hoc analysis).
this context and is able to orchestrate the inflammatory response
(33–35). However, its role in the neonatal brain has not yet been
elucidated, even if caffeine, a non-specific adenosine antagonist,
has shown an important neuroprotective role in premature
infants.
The adenosine system appears to be involved in regulating
inflammation in both acute (IBO) and chronic (LPD) neuro-
inflammation in vivo. The two animal models used in the present
study display alterations that occur at a developmental stage of
the rat brain that corresponds to the human brain at 28–32
gestation weeks (GW) (36). This window is recognized as a
period of high vulnerability for the developing brain to either
excitotoxic or inflammatory insults (37). Interestingly, these
effects are exerted through themodulation ofmicroglia reactivity,
that, as previously reported (23, 38), characterizes the two animal
models.
In conditions of inflammation, oxidative stress, excitotoxicity
or cellular necrosis, the purinergic system is the first to
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FIGURE 6 | Effect of ibotenate exposure to microglial cell cultures on gene expression of enzymes involved in the production of adenosine and its receptors. Data are
shown as relative expression of control values (PBS exposure) set to 1 for each time-point. (*p < 0.05, **p < 0.01, ***p < 0.001, using unpaired Student’s t-test).
CD73, cluster of differentiation 73; A2aR, adenosine A2a receptor; A1R, adenosine A1 receptor; ADA, adenosine deaminase; A2bR, adenosine A2b receptor; A3R,
adenosine A3 receptor.
be involved (39). Indeed, under pathological conditions,
extracellular ATP is produced by both neurons and glial cells (40)
and is rapidly converted to ADP and AMP by Entpd1 and by
CD73, which convert AMP to adenosine (41). Despite its very
short half-life (few seconds), increased adenosine brain levels
contributes to induction and modulation of neuro-inflammation
(42).
To assess the adenosine implication in the LPD model, an
adenosine assay on whole blood was performed. Since deliveries
can span a 12-h and to avoid the stressful peak related to delivery,
the blood samples were collected at P1, when LPD pups showed
higher level of adenosine blood levels compared to controls.
As described for human neonates (43), delivery is responsible
for a physiological increase in adenosine blood levels in the
newborn. Interestingly, adenosine blood levels remained higher
in LPD at P4 in our study, when the effects of delivery have
disappeared.
Remarkably, the increasing adenosine blood levels in LPD rats
are similar to those found in premature infants (20) and suggest
a pro-inflammatory condition that characterizes these babies
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FIGURE 7 | A2aR expression in sorted microglial cells exposed to ibotenate (IBO). (A) A2aR (red) and Iba-1 (green) immunoreactivity in microglial cells sorted from P4
rat pups after 6 h IBO or PBS exposure (scale bar: 50µm). (B,C) Quantification of mean fluorescence for Iba-1 and A2aR immunoreactivity in PBS and IBO-exposed
cells. (D) Quantification of cell size on Iba-1 positive cells. Data are shown as relative expression of PBS values normalized to 1 (***p < 0.001, using unpaired Student’s
t-test).
from birth until the first month of life. Similarly to neonates,
LPD pups also showed a chronic inflammatory condition, as
a result of maternal malnutrition, with a detrimental effect on
neurodevelopment (23). In the brain, CD73, also known as Nt5e,
is considered as the principal enzyme involved in the production
of extracellular adenosine (44). The mRNA expression of the two
ectonucleotidases Entpd1 andCD73, responsible for the final step
of ATP catabolism into adenosine, is significantly increased in
LPD both at P1 and P4. These results are in agreement with the
study conducted by Chen et al. who reported that the activity of
the ectonucleotidases is stimulated by inflammatory conditions
(45).
Adenosine elicits its physiological responses by binding
to and activating one or more of the four transmembrane
ARs. Solid evidence demonstrated that the four receptors are
all expressed in the brain (33) and our results confirm the
expression of all ARs in the rat pup cortex. Interestingly,
LPD animals displayed an increased expression of A2aR and
A2bR, known to exert a pro-inflammatory action (14, 46), in
the pre-frontal cortex both at P1 and P4. In the LPD model,
which induces fetal growth restriction, the main alteration
consists in disturbance of oligodendrocytes progenitor cells
(OPC) maturation conducing to a deficit of myelination, that
occurred in combination with a proinflammatory state evidenced
by transcriptomic analysis performed in sorted microglia (23).
Our in vitro results revealed that microglial cells sorted from rat
pups subjected to LPD have abnormal reactivity with increased
Iba1 staining and smaller size, when compared to control cells.
Iba1 is constitutively expressed by microglia and is involved
in the actin-crosslinking associated with membrane ruffling
of microglial cells, an event essential for the morphological
changes from quiescent ramifiedmicroglia to activated amoeboid
microglia (47). Furthermore, the reduction in cell size has
been shown to be strongly correlated to microglial activation
(48, 49).
Regarding the potential role of adenosine in the modulation
onmicroglia activity, we reported an increase in A2aR transcripts
and protein levels in LPD-exposed microglia cells. A2aR has
an important role in the control of inflammatory events
(14) by regulating microglial reactivity, changing microglial
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FIGURE 8 | A2aR modulation regulates the phenotype of microglial sorted cells exposed to 300µM ibotenate (IBO) for 6 h. Quantification of gene relative expressions
of M1 (A) and M2 (B) proteins in microglial cells treated with or without SCH-58261 (A2aR antagonist) and CGS-21680 (A2aR agonist) sorted from control or LPD
animals (*p < 0.05, **p < 0.01, ***p < 0.001, using one-way ANOVA followed by Newman-Keuls post-hoc analysis).
morphology (16), increasing the release of cytokines and
prostaglandin E2 (15) and nitric oxide synthase activity.
In addition to A2aR, CD73 has been shown to have an
important role in modulation of microglia ramification
and activation (51). These data are consistent with our
findings and support a possible role of adenosine in the
regulation of the inflammatory response following brain
injury.
The results of in vitro studies conducted using an A2aR
pharmacological approach clearly evidenced the involvement
of A2aR in the regulation of inflammatory response in LPD
model. These results are well supported by previous studies,
which demonstrated that A2aR antagonists suppress microglia
activation and IL-1β secretion in murine microglial cells exposed
to an inflammatory stimulus induced by LPS (17, 18). A2aR
gene disruption in mice showed a lower severity of inflammatory
response and subsequent damage in different models of brain
injury including ischemia/hypoxia and traumatic brain injury
(50–52).
On the other hand, treatment with CGS-21680, an A2aR
selective agonist, promotes the increase in M1 markers in LPD
microglial cells suggesting that chronic inflammation causes
microglial cells to be more susceptible to the pro-inflammatory
effect of adenosine via A2a receptors.
The Ibotenate model closely mimics the pathological features
observed in periventricular white matter (38). In this model
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FIGURE 9 | Measurement of cytokine concentrations in culture media collected 12 h after 300µM ibotenate (IBO) exposure in microglial cells pre-treated with or
without SCH. (*p < 0.05, **p < 0.01, ***p < 0.001, using one-way ANOVA followed by Newman–Keuls post-hoc analysis).
of acute brain injury and inflammation, both in vivo and
in vitro findings support the involvement of A2aR. However,
some features of microglial activation in vitro appear to be
different from those observed in the LPD model, as microglial
cells treated by ibotenate showed no difference in cell size and
Iba1 expression. In conclusion this study gives evidence of
the involvement of adenosine and in particular of its receptor
A2aR in the regulation of microglia in two models of perinatal
brain injury associated with neuro-inflammation. The present
study focused only on the relation between adenosine formation
and A2aR inactivation; it remains to be explored whether
the other receptors might play a role in the regulation of
microglia in the same models of perinatal brain injury. Indeed,
all the 4 receptors subtypes are non-specifically inactivated
by caffeine. Further studies may provide a functional role
for caffeine and specific antagonists of the remaining ARs
in the limitation of perinatal brain injury associated with
neuro-inflammation. In summary, the present study suggests
that A2aR, up-regulated as consequence of inflammation, can
influence the microglia phenotype, building up a potential for
A2aR antagonist as a therapeutic strategy for neonatal brain
damage.
AUTHOR CONTRIBUTIONS
MC, JM, LR, and OB designed the study. MC, MZ, and
JP performed experiments. MCa performed adenosine
measurements. MC, JM, and OB wrote the paper. All authors
revised and approved final version of the manuscript.
FUNDING
This study was supported by Inserm, France and by University of
Genoa, Italy.
ACKNOWLEDGMENTS
We thankAudrey Toulotte-Aebi for the editing of themanuscript
draft.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: https://www.frontiersin.org/articles/10.3389/fneur.
2018.00605/full#supplementary-material
Frontiers in Neurology | www.frontiersin.org 12 September 2018 | Volume 9 | Article 605
Colella et al. Microglial Activation and Adenosine A2aR
REFERENCES
1. Volpe JJ. Neurology of the Newborn. 5th edition. Philadelphia, PA: Elsevier
Health Sciences (2008).
2. Back SA. White matter injury in the preterm infant: pathology
and mechanisms. Acta Neuropathol. (2017) 134:331–49.
doi: 10.1007/s00401-017-1718-6
3. Hagberg H, Gressens P, Mallard C. Inflammation during fetal and neonatal
life: implications for neurologic and neuropsychiatric disease in children and
adults. Ann Neurol. (2012) 71:444–57. doi: 10.1002/ana.22620
4. Fleiss B, Gressens P. Tertiary mechanisms of brain damage: a new
hope for treatment of cerebral palsy? Lancet Neurol. (2012) 11:556–66.
doi: 10.1016/S1474-4422(12)70058-3
5. Rezaie P, Dean A. Periventricular leukomalacia, inflammation and white
matter lesions within the developing nervous system. Neuropathology (2002)
22:106–32. doi: 10.1046/j.1440-1789.2002.00438.x
6. Dammann O, Leviton A. Inflammatory brain damage in preterm newborns -
Dry numbers, wet lab, and causal inferences. Early Hum Dev. (2004) 79:1–15.
doi: 10.1016/j.earlhumdev.2004.04.009
7. Miller JE, Pedersen LH, Streja E, Bech BH, Yeargin-Allsopp M, Van Naarden
Braun K, et al. Maternal infections during pregnancy and cerebral palsy: a
population-based cohort study. Paediatr Perinat Epidemiol. (2013) 27:542–52.
doi: 10.1111/ppe.12082
8. Knuesel I, Chicha L, Britschgi M, Schobel SA, Bodmer M, Hellings JA, et al.
Maternal immune activation and abnormal brain development across CNS
disorders. Nat Rev Neurol. (2014) 10:643–60. doi: 10.1038/nrneurol.2014
9. Hagberg H, Mallard C, Ferriero DM, Vannucci SJ, Levison SW, Vexler ZS, et
al. The role of inflammation in perinatal brain injury. Nat Rev Neurol. (2015)
11:192–208. doi: 10.1038/nrneurol.2015.13
10. Chhor V, Le Charpentier T, Lebon S, Oré MV, Celador IL, Josserand J, et
al. Characterization of phenotype markers and neuronotoxic potential of
polarised primary microglia in vitro. Brain Behav Immun. (2013) 32:70–85.
doi: 10.1016/j.bbi.2013.02.005
11. Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M.
The chemokine system in diverse forms of macrophage activation and
polarization. Trends Immunol. (2004) 25:677–86. doi: 10.1016/j.it.2004.09.015
12. Rivkees SA, Wendler CC. Adverse and protective influences of
adenosine on the newborn and embryo: implications for preterm white
matter injury and embryo protection. Pediatr Res. (2011) 69:271–8.
doi: 10.1203/PDR.0b013e31820efbcf
13. Fredholm BB, Yang J, Wang Y. Low, but not high, dose cafeine is a readily
available probe for adenosine actions. Mol Aspects Med. (2016) 55:20–5.
doi: 10.1016/j.mam.2016.11.011
14. Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in
downregulation of inflammation and protection from tissue damage. Nature
(2001) 414:916–20. doi: 10.1038/414916a
15. Minghetti L, Greco A, Potenza RL, Pezzola A, Blum D, Bantubungi K,
et al. Effects of the adenosine A2A receptor antagonist SCH 58621 on
cyclooxygenase-2 expression, glial activation, and brain-derived neurotrophic
factor availability in a rat model of striatal neurodegeneration. J Neuropathol
Exp Neurol. (2007) 66:363–71. doi: 10.1097/nen.0b013e3180517477
16. Orr AG, Orr AL, Li X-J, Gross RE, Traynelis SF. Adenosine A2A receptor
mediates microglial process retraction. Nat Neurosci. (2009) 12:872–8.
doi: 10.1038/nn.2341
17. Gomes C, Ferreira R, George J, Sanches R, Rodrigues DI, Gonçalves N,
et al. Activation of microglial cells triggers a release of brain-derived
neurotrophic factor (BDNF) inducing their proliferation in an adenosine
A2A receptor-dependent manner: A2A receptor blockade prevents BDNF
release and proliferation of microglia. J Neuroinflammation (2013) 30:10–6.
doi: 10.1186/1742-2094-10-16
18. Rebola N, Simões AP, Canas PM, Tomé AR, Andrade GM, Barry CE, et
al. Adenosine A2A receptors control neuroinflammation and consequent
hippocampal neuronal dysfunction. J Neurochem. (2011) 117:100–11.
doi: 10.1111/j.1471-4159.2011.07178.x
19. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, et al.
Long-term effects of caffeine therapy for apnea of prematurity. N Engl J Med.
(2007) 357:1893–902. doi: 10.1056/NEJMoa073679
20. Panfoli I, Cassanello M, Bruschettini M, Colella M, Cerone R, Ravera S, et al.
Why do premature newborn infants display elevated blood adenosine levels?
Med Hypotheses (2016) 90:53–6. doi: 10.1016/j.mehy.2016.03.007
21. Atik A, Harding R, De Matteo R, Kondos-Devcic D, Cheong J, Doyle LW,
et al. Caffeine for apnea of prematurity: Effects on the developing brain.
Neurotoxicology (2017) 58:94–102. doi: 10.1016/j.neuro.2016.11.012
22. Zana-Taieb E, Butruille L, Franco-Montoya M-L, Lopez E, Vernier F,
Grandvuillemin I, et al. Effect of two models of intrauterine growth restriction
on alveolarization in rat lungs: morphometric and gene expression analysis.
PLoS ONE (2013) 8:e78326. doi: 10.1371/journal.pone.0078326
23. Rideau Batista Novais A, PhamH, Van de Looij Y, Bernal M, Mairesse J, Zana-
Taieb E, et al. Transcriptomic regulations in oligodendroglial and microglial
cells related to brain damage following fetal growth restriction. Glia (2016)
64:2306–20. doi: 10.1002/glia.23079.
24. Pansiot J, Loron G, Olivier P, Fontaine R, Charriaut-Marlangue C, Mercier
JC, et al. Neuroprotective effect of inhaled nitric oxide on excitotoxic-
induced brain damage in neonatal rat. PLoS ONE (2010) 5:e10916.
doi: 10.1371/journal.pone.0010916
25. Madeira MH, Elvas F, Boia R, Goncalves FQ, Cunha RA, Ambrosio AF, et
al. Adenosine A2AR blockade prevents neuroinflammation-induced death of
retinal ganglion cells caused by elevated pressure. J Neuroinflammation (2015)
12:115. doi: 10.1186/s12974-015-0333-5.
26. Newell EA, Exo JL, Verrier JD, Jackson TC, Gillespie DG, Janesko-Feldman K,
et al. 2’,3’-cAMP, 3’-AMP, 2’-AMP and adenosine inhibit TNF-α and CXCL10
production from activated primary murine microglia via A(2A) receptors.
Brain Res. (2015) 1594:27–35. doi: 10.1016/j.brainres.2014.10.059
27. van der Putten C, Zuiderwijk-Sick E a, van Straalen L, de Geus ED, Boven LA,
Kondova I, et al. Differential expression of adenosine A3 receptors controls
adenosine A2A receptor-mediated inhibition of TLR responses in microglia. J
Immunol. (2009) 182:7603–12. doi: 10.4049/jimmunol.0803383
28. Kaindl AM, Degos V, Peineau S, Gouadon E, Chhor V, Loron G,
et al. Activation of microglial N-methyl-D-aspartate receptors triggers
inflammation and neuronal cell death in the developing and mature brain.
Ann Neurol. (2012) 72:536–49. doi: 10.1002/ana.23626
29. Kuban KCK, O’Shea TM, Allred EN, Fichorova RN, Heeren T, Paneth N, et
al. The breadth and type of systemic inflammation and the risk of adverse
neurological outcomes in extremely low gestation newborns. Pediatr Neurol.
(2015) 52:42–8. doi: 10.1016/j.pediatrneurol.2014.10.005
30. Otsubo Y, Hashimoto K, Kanbe T, Sumi M, Moriuchi H. Association of
cord blood chemokines & other biomarkers with neonatal complications
following intrauterine inflammation. PLoS ONE (2017) 12:e0175082.
doi: 10.1371/journal.pone.0175082
31. Rezaie P, Dean A, Male D, Ulfig N. Microglia in the cerebral wall of the
human telencephalon at second trimester. Cereb Cortex (2005) 15:938–49.
doi: 10.1093/cercor/bhh194
32. Lehnardt S, Massillon L, Follett P, Jensen FE, Ratan R, Rosenberg PA, et
al. Activation of innate immunity in the CNS triggers neurodegeneration
through a Toll-like receptor 4-dependent pathway. Proc Natl Acad Sci USA.
(2003) 100:8514–9. doi: 10.1073/pnas.1432609100
33. Haskó G, Linden J, Cronstein B, Pacher P. Adenosine receptors: therapeutic
aspects for inflammatory and immune diseases. Nat Rev Drug Discov (2008)
7:759–70. doi: 10.1038/nrd2638
34. Wei CJ, Li W, Chen JF. Normal and abnormal functions of
adenosine receptors in the central nervous system revealed by
genetic knockout studies. Biochim Biophys Acta (2011)1808:1358–79.
doi: 10.1016/j.bbamem.2010.12.018
35. Chen JF, Lee C fei, Chern Y. Adenosine receptor neurobiology: overview. Int
Rev Neurobiol. (2014) 119:1–49. doi: 10.1016/B978-0-12-801022-8.00001-5
36. Whitelaw A, Thoresen M. Antenatal steroids and the developing brain. Arch
Dis Child (2000) 83:154–57. doi: 10.1136/fn.83.2.F154
37. Haynes RL, Baud O, Li J, Kinney HC, Volpe JJ, Folkerth DR. Oxidative and
nitrative injury in periventricular leukomalacia: a review. Brain Pathol. (2005)
15:225–33. doi: 10.1111/j.1750-3639.2005.tb00525.x
38. Dommergues MA, Plaisant F, Verney C, Gressens P. Early microglial
activation following neonatal excitotoxic brain damage in mice: a
potential target for neuroprotection. Neuroscience (2003) 121:619–28.
doi: 10.1016/S0306-4522(03)00558-X
Frontiers in Neurology | www.frontiersin.org 13 September 2018 | Volume 9 | Article 605
Colella et al. Microglial Activation and Adenosine A2aR
39. Eltzschig HK, Sitkovsky MV, Robson SC. Purinergic signaling
during inflammation. N Engl J Med. (2012) 367:2322–33.
doi: 10.1056/NEJMra1205750
40. Elliott MR, Chekeni FB, Trampont PC, Lazarowski ER, Kadl A, Walk SF,
et al. Nucleotides released by apoptotic cells act as a find-me signal to
promote phagocytic clearance. Nature (2009) 461:282–6. doi: 10.1038/nature
08296
41. Eltzschig HK, Weissmüller T, Mager A, Eckle T. Nucleotide metabolism
and cell-cell interactions. Methods Mol Biol. (2006) 341:73–87.
doi: 10.1385/1-59745-113-4:73
42. Di Virgilio F, Ceruti S, Bramanti P, Abbracchio MP. Purinergic signalling
in inflammation of the central nervous system. Trends Neurosci. (2009)
32:79–87. doi: 10.1016/j.tins.2008.11.003
43. Irestedt L, Dahlin I, Hertzberg T, Sollevi A, Lagercrantz H. Adenosine
concentration in umbilical cord blood of newborn infants after vaginal
delivery and cesarean section. Pediatr Res. (1989) 26:106–8.
44. Lovatt D, Xu Q, Liu W, Takano T, Smith NA, Schnermann J, et al.
Neuronal adenosine release, and not astrocytic ATP release, mediates feedback
inhibition of excitatory activity. Proc Natl Acad Sci USA. (2012) 109:6265–70.
doi: 10.1073/pnas.1120997109
45. Augusto E, Matos M, Sevigny J, El-Tayeb A, Bynoe MS, Muller CE, et al.
Ecto-5’-nucleotidase (CD73)-mediated formation of adenosine is critical for
the striatal adenosine A2A receptor functions. J Neurosci. (2013) 33:11390–9.
doi: 10.1523/JNEUROSCI.5817-12.2013
46. Schulte G, Fredholm BB. Signalling from adenosine receptors to
mitogen-activated protein kinases. Cell Signal (2003) 15:813–27.
doi: 10.1016/S0898-6568(03)00058-5
47. Sasaki Y, Ohsawa K, Kanazawa H, Kohsaka S, Imai Y. Iba1 is an actin-cross-
linking protein in macrophages/microglia. Biochem Biophys Res Commun.
(2001) 286:292–7. doi: 10.1006/bbrc.2001.5388
48. Kozlowski C, Weimer RM. An automated method to quantify microglia
morphology and application to monitor activation state longitudinally in vivo.
PLoS ONE (2012) 7:e0031814. doi: 10.1371/journal.pone.0031814
49. Hovens I, Nyakas C, Schoemaker R. A novel method for evaluating microglial
activation using ionized calcium-binding adaptor protein-1 staining: cell
body to cell size ratio. Neuroimmunol Neuroinflammat. (2014) 1:82.
doi: 10.4103/2347-8659.139719
50. Yu L, Huang Z, Mariani J, Wang Y, Moskowitz M, Chen J-F. Selective
inactivation or reconstitution of adenosine A2A receptors in bone marrow
cells reveals their significant contribution to the development of ischemic
brain injury. Nat Med. (2004) 10:1081–7. doi: 10.1038/nm1103
51. Li W, Dai S, An J, Xiong R, Li P, Chen X, et al. Genetic inactivation
of adenosine A2A receptors attenuates acute traumatic brain injury
in the mouse cortical impact model. Exp Neurol. (2009) 215:69–76.
doi: 10.1111/j.1471-4159.2012.07807.x
52. Yu L, Shen H-Y, Coelho JE, Araújo IM, Huang Q-Y, Day Y-J, et al. Adenosine
A2A receptor antagonists exert motor and neuroprotective effects by distinct
cellular mechanisms. Ann Neurol. (2008) 63:338–46. doi: 10.1002/ana.21313
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2018 Colella, Zinni, Pansiot, Cassanello, Mairesse, Ramenghi and Baud.
This is an open-access article distributed under the terms of the Creative Commons
Attribution License (CC BY). The use, distribution or reproduction in other forums
is permitted, provided the original author(s) and the copyright owner(s) are credited
and that the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.
Frontiers in Neurology | www.frontiersin.org 14 September 2018 | Volume 9 | Article 605
